Evidence map›Paper›PMID 39812038›Full record

ReviewCurrent vascular pharmacology2025

Promising Adventitia in Atherosclerosis.

Maolin Qiao, Ruijing Zhang, Xuezhen Xuan, Sheng Yan, Honglin Dong

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current vascular pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maolin QiaoDepartment of Vascular Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Ruijing ZhangDepartment of Nephrology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Xuezhen XuanDepartment of Vascular Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Sheng YanDepartment of Vascular Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.
Honglin DongDepartment of Vascular Surgery, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The adventitia, the artery's most intricate layer, has received little attention. During atherosclerosis, adventitia components undergo significant changes, such as angiogenesis, lymphangiogenesis, Artery Tertiary Lymphoid Organ (ATLO) formation, axon density increase, fibroblast activation, and stem cell differentiation. The reasons behind these changes and their contribution to atherosclerosis are beginning to be understood. In this review, we summarize the adventitia components and their role in normal arteries and then discuss the changes, pathogenesis, and potential clinical application of the adventitia in atherosclerosis.

Indexed as

AdventitiaArteriesAtherosclerosisAnimalsCell DifferentiationHumansLymphangiogenesisNeovascularization, PathologicPlaque, AtheroscleroticVascular Remodelingadventitiaartery tertiary lymphoid organsAtherosclerosisfibroblast.pathogenesisvasa vasorum

Identifiers

PMID39812038

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.